SFG 02
Alternative Names: SFG-02Latest Information Update: 23 Dec 2025
At a glance
- Originator Juro Sciences
- Class Small molecules; Urologics
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bladder dysfunction
Most Recent Events
- 18 Sep 2025 Pharmacodynamics and pharmacokinetics data from the preclinical studies in Bladder dysfunction released by Juro Sciences
- 11 Sep 2025 Phase-I clinical trials in Bladder dysfunction (In volunteers) in Japan (Transdermal) prior to September 2025 (NCT07167914)
- 10 Sep 2025 Juro Sciences has patent pending application for SFG 02